Education:

• 2000: Master in Pharmacology and Toxicology, Sapienza University of Rome
• 1987: degree cum laude in Pharmacy, Sapienza University of Rome
• 1985: degree cum laude in Chemistry and Pharmaceutical Technologies, Sapienza University of Rome 

Positions:

• 2020 Teaching position of Pharmacology at Sapienza University of Rome, Faculty of Medicine and Pharmacy, Master degree in Nursing and Midwifery Sciences, Corso di laurea A – Azienda Policlinico Umberto I
• 2018 Referent of IBCN Research Unit p/o Sense Organs Department, Sapienza, University of Rome
• 2018: Teaching position of Pharmacology at Sapienza University of Rome, Faculty of Medicine and Pharmacy, Master Degree Applied Pharmaceutical Sciences
• 2017: Responsible of URT IBCN, Fondazione EBRI Rita Levi-Montalcini
• 2016: Supply teaching board member, PhD School in Pharmacology, Sapienza University of Rome
• 2001: Research Scientist INMM, CNR, Rome
• 2000: Research scientist, CNR INMM, Rome
• 1991-2000: Supply Teacher in Pharmacognosy and Pharmacological Sciences , Faculty of Pharmacy, Sapienza University of Rome

Dr. Severini has published about 100 articles/invited reviews in internationals journals and is Gest Editor of a Topic Special Issues in Cells (2020): “Neurotrophic factors in health and disease”. Dr. Severini collaborates to the Reviewers board of Frontiers in Neuroscience and Frontiers in Pharmacology, Experimental Pharmacology and Drug Discovery.
H Index: 29
Orcid ID   0000-0002-6932-704X

Honours/Awards:

2013: Qualification for University Associate Professor (05/F1)

2013 Award for Best Poster at Telethon Conventions, Italy

2011 Award for Best Poster at Telethon Conventions, Italy

Ongoing Research Support:

2018-2021: Lazio Innova Project 15286 Passananti (PI). Title: “Geni artificiali come strategia terapeutica per la Distrofia muscolare di Duchenne”/“Artificial genes as therapeutic strategy for Duchenne Muscular Dystrophy”. Role: Co-Investigator

2020: Progetto Medio Ateneo Sapienza Università di Roma (2019). Characterization of the Secretogranin VGF (SgVII) in laryngeal carcinoma to identify a new potential tumor marker. Role: Co-Investigator

Patents:

Levi A, Possenti R, Severini C. Peptide in grado di indurre la contrazione muscolare e suoi usi. RM2001A000439, 23 Luglio 2001.

• Lattanzi R, Maftei D, Petrella C, Pieri M, Sancesario G, Schirinzi T, Bernardini S, Barbato C, Ralli M, Greco A, Possenti R, Sancesario G, Severini C*. Involvement of the chemokine Prokineticin-2 (PROK2) in Alzheimer’s disease: from animal models to the human pathology. Cells, 2019; pii: E1430. IF: 5.3
• Severini C*, Lattanzi R, Maftei D, Marconi V, Ciotti MT, Petrocchi Passeri P, Florenzano F, Del Duca E, Caioli S, Zona C, Balboni G, Salvadori S, Nisticò R, Negri L. Bv8/prokineticin 2 is involved in Aβ-induced neurotoxicity. Sci Rep. 2015;5:15301. IF: 4.5
• Marolda R, Ciotti MT, Matrone C, Possenti R, Calissano P, Cavallaro S, Severini C*. Substance P activates ADAM9 mRNA expression and induces α-secretase-mediated amyloid precursor protein cleavage. Neuropharmacology. 2012;62:1954-63. IF: 4.4
• Severini C*, La Corte G, Improta G, Broccardo M, Agostini S, Petrella C, Sibilia V, Pagani F, Guidobono F, Bulgarelli I, Ferri GL, Brancia C, Rinaldi AM, Levi A, Possenti R. In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. Br J Pharmacol. 2009;157:984-93. IF: 6.6
• Severini C*, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev. 2002;54:285-322. IF: 19

Dal 2008                 
Telethon GGP14073A (2014-2015)
Telethon GGP10094 2013
FIRB RBAP10L8TY_004 (2011-2012)
FIRB RBLA03FLJC_010 (2008-2009)

2016-2018
Progetto invecchiamento DSB.AD009.001 (2016-2018)